Literature DB >> 19727528

Anti-tumor activity and immunological modification of ribosome-inactivating protein (RIP) from Momordica charantia by covalent attachment of polyethylene glycol.

Mengen Li1, Yiwen Chen, Zhongyu Liu, Fubing Shen, Xiaoxiao Bian, Yanfa Meng.   

Abstract

Ribosome-inactivating proteins (RIPs) are a family of enzymes that depurinate rRNA and inhibit protein biosynthesis. Here we report the purification, apoptosis-inducing activity, and polyethylene glycol (PEG) modification of RIP from the bitter melon seeds. The protein has a homogenous N-terminal sequence of NAsp- Val-Ser-Phe-Arg. Moreover, the RIP displayed strong apoptosis-inducing activity and suppressed cancer cell growth. This might be attributed to the activation of caspases-3. To make it available for in vivo application, the immunogenicity of RIP was reduced by chemical modification with 20 kDa (mPEG)(2)-Lys-NHS. The inhibition activity of both PEGylated and non-PEGylated RIP against cancer cells was much stronger than against normal cells, and the antigenicity of PEGylated RIP was reduced significantly. Our results suggested that the PEGylated RIP might be potentially developed as anti-cancer drug.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19727528     DOI: 10.1093/abbs/gmp068

Source DB:  PubMed          Journal:  Acta Biochim Biophys Sin (Shanghai)        ISSN: 1672-9145            Impact factor:   3.848


  13 in total

1.  Bitter melon extract impairs prostate cancer cell-cycle progression and delays prostatic intraepithelial neoplasia in TRAMP model.

Authors:  Peng Ru; Robert Steele; Pratibha V Nerurkar; Nancy Phillips; Ratna B Ray
Journal:  Cancer Prev Res (Phila)       Date:  2011-09-12

Review 2.  Bitter melon: antagonist to cancer.

Authors:  Pratibha Nerurkar; Ratna B Ray
Journal:  Pharm Res       Date:  2010-03-03       Impact factor: 4.200

3.  Effect of α, β momorcharin on viability, caspase activity, cytochrome c release and on cytosolic calcium levels in different cancer cell lines.

Authors:  Gunasekar Manoharan; Seema R Jaiswal; Jaipaul Singh
Journal:  Mol Cell Biochem       Date:  2013-12-03       Impact factor: 3.396

4.  Preparation of an antitumor and antivirus agent: chemical modification of α-MMC and MAP30 from Momordica Charantia L. with covalent conjugation of polyethyelene glycol.

Authors:  Yao Meng; Shuangfeng Liu; Juan Li; Yanfa Meng; Xiaojun Zhao
Journal:  Int J Nanomedicine       Date:  2012-06-27

Review 5.  Ribosome-inactivating proteins: potent poisons and molecular tools.

Authors:  Matthew J Walsh; Jennifer E Dodd; Guillaume M Hautbergue
Journal:  Virulence       Date:  2013-09-17       Impact factor: 5.882

6.  Electrozymographic evaluation of the attenuation of arsenic induced degradation of hepatic SOD, catalase in an in vitro assay system by pectic polysaccharides of Momordica charantia in combination with curcumin.

Authors:  Hasina Perveen; Moumita Dash; Shamima Khatun; Moulima Maity; Syed Sirajul Islam; Sandip Chattopadhyay
Journal:  Biochem Biophys Rep       Date:  2017-06-23

7.  Evaluation of in vitro cytotoxic activity of mono-PEGylated StAP3 (Solanum tuberosum aspartic protease 3) forms.

Authors:  Fernando Muñoz; Pablo C Caracciolo; Gustavo Daleo; Gustavo A Abraham; M Gabriela Guevara
Journal:  Biotechnol Rep (Amst)       Date:  2014-05-27

8.  Momordica charantia Extract Induces Apoptosis in Human Cancer Cells through Caspase- and Mitochondria-Dependent Pathways.

Authors:  Chia-Jung Li; Shih-Fang Tsang; Chun-Hao Tsai; Hsin-Yi Tsai; Jong-Ho Chyuan; Hsue-Yin Hsu
Journal:  Evid Based Complement Alternat Med       Date:  2012-10-04       Impact factor: 2.629

9.  Effect of superfine grinding on antidiabetic activity of bitter melon powder.

Authors:  Ying Zhu; Ying Dong; Xiwen Qian; Fengjie Cui; Qin Guo; Xinghua Zhou; Yun Wang; Yi Zhang; Zhiyu Xiong
Journal:  Int J Mol Sci       Date:  2012-11-02       Impact factor: 5.923

10.  A novel method for simultaneous production of two ribosome-inactivating proteins, α-MMC and MAP30, from Momordica charantia L.

Authors:  Yao Meng; Sen Lin; Shuangfeng Liu; Xiang Fan; Gangrui Li; Yanfa Meng
Journal:  PLoS One       Date:  2014-07-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.